Woori IO’s pain-free glucose monitor achieves high precision in OSR Holdings pilot test
Find out how OSR Holdings and Woori IO are redefining glucose monitoring through a pain-free optical device that could transform diabetes care. Read More
Artivion (NYSE: AORT) begins pivotal Arcevo LSA trial: Could this hybrid stent unlock an $80m U.S. market?
Artivion begins pivotal ARTIZEN trial with first patient treated using Arcevo LSA. Find out how this hybrid stent could transform aortic arch surgery. Read More
Why 10X Health, REVIV, and M42 chose Abu Dhabi to launch the world’s most advanced nutrition system
Discover how 10X Health, REVIV Global, and M42 are bringing a DNA-driven Precision Nutrition System to Abu Dhabi and setting a new longevity benchmark. Read More
Why Four Corners Property Trust just paid $3.9m for an outpatient care center in Alabama
Four Corners Property Trust acquires an SCA Health site in Alabama for $3.9M at an 8.3% cap rate. Find out what this signals for healthcare ... Read More
Can Beyond Air’s $32m lifeline drive profitability and global adoption of LungFit PH?
Find out how Beyond Air’s $32 million lifeline could drive profitability and global adoption of its LungFit PH nitric oxide therapy device. Read More
VSee Health wins three-year telehealth platform deal with leading Level 1 trauma and academic system
Discover how VSee Health’s three-year telehealth deal with a leading Level 1 trauma and academic system could transform enterprise virtual care delivery. Read More
Imricor Medical Systems (ASX: IMR) jumps 11% after world’s first MRI-guided ischemic VT ablation
Imricor (ASX: IMR) jumps 11% after achieving the first-ever MRI-guided ischemic VT ablation. Discover how this breakthrough could redefine cardiac care worldwide. Read More
LSE: ITRK expands in Latin America—What does Intertek’s Suplilab buy mean for food and medtech testing?
Intertek Group Plc expands into Central America with the acquisition of Suplilab. Find out how this move boosts its ATIC presence in food and medical ... Read More
Anteris edges closer to FDA IDE approval for DurAVR PARADIGM trial after promising clinical data
Find out how Anteris’s DurAVR transcatheter heart valve is advancing toward a global pivotal trial and what it means for the structural heart market. Read More
From trash to treasure: Waste Management Inc.’s $3.8bn free cash flow bet for 2026 explained
Discover how Waste Management Inc. is targeting $3.8 billion in free cash flow by 2026 and why that could reshape the waste and recycling industry. Read More